Cytokinetics Incorporated (NASDAQ:CYTK)’s traded shares stood at 2.43 million during the last session, with the company’s beta value hitting 0.84. At the close of trading, the stock’s price was $35.33, to imply a decrease of -4.67% or -$1.73 in intraday trading. The CYTK share’s 52-week high remains $55.80, putting it -57.94% down since that peak but still an impressive 4.9% since price per share fell to its 52-week low of $33.60. The company has a valuation of $3.48B, with an average of 1.24 million shares in intraday trading volume over the past 10 days and average of 952.73K shares over the past 3 months.
Analysts have given a consensus recommendation of a Buy for Cytokinetics Incorporated (CYTK), translating to a mean rating of 1.90. Of 16 analyst(s) looking at the stock, 0 analyst(s) give CYTK a Sell rating. 2 of those analysts rate the stock as Overweight while 1 advise Hold as 13 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -$1.21.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
Cytokinetics Incorporated (NASDAQ:CYTK) trade information
After registering a -4.67% downside in the last session, Cytokinetics Incorporated (CYTK) has traded red over the past five days. The stock hit a weekly high of 38.38 this Friday, 03/17/23, dropping -4.67% in its intraday price action. The 5-day price performance for the stock is -0.76%, and -17.59% over 30 days. With these gigs, the year-to-date price performance is -22.89%. Short interest in Cytokinetics Incorporated (NASDAQ:CYTK) saw shorts transact 9.98 million shares and set a 11.5 days time to cover.
Analysts on Wall Street suggest a consensus price target of $61.75, implying an increase of 42.79% to the stock’s current value. The extremes give us $48.00 and $80.00 for target low and target high price respectively. As such, CYTK has been trading -126.44% off suggested target high and -35.86% from its likely low.
Cytokinetics Incorporated (CYTK) estimates and forecasts
Looking at statistics comparing Cytokinetics Incorporated share performance against respective industry, we note that the company has underperformed competitors. Cytokinetics Incorporated (CYTK) shares are -34.94% down over the last 6 months, with its year-to-date growth rate lower than industry average at -8.62% against 9.60%. Revenue is forecast to shrink -236.10% this quarter before falling -13.30% for the next one. The rating firms project that company’s revenue will grow 40.80% compared to the previous financial year.
Revenue forecast for the current quarter as set by 13 analysts is $7.45 million. Meanwhile, for the quarter ending Mar 2023, a total of 4 analyst(s) estimate revenue growth to $23.27 million.Earnings reports from the last fiscal year show that sales brought in $55.6 million and $1.15 million respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -86.60% before jumping 1,927.00% in the following quarter.
An assessment of the company’s 5-year growth patterns shows that annual earnings shrunk an estimated -10.90% for the past 5-year period. While 2023 is set for a -54.60% return in earnings, projections for the next 5 years are at 15.00% annually.
Cytokinetics Incorporated has its next earnings report out between May 02 and May 08. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Cytokinetics Incorporated has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
Cytokinetics Incorporated (NASDAQ:CYTK)’s Major holders
Cytokinetics Incorporated insiders hold 1.16% of total outstanding shares, with institutional holders owning 117.87% of the shares at 119.26% float percentage. In total, 117.87% institutions holds shares in the company, led by Blackrock Inc. As of Sep 29, 2022, the company held over 14.57 million shares (or 15.40% of shares), all amounting to roughly $705.92 million.
The next major institution holding the largest number of shares is FMR, LLC with 12.89 million shares, or about 13.62% of shares outstanding. As of the market price on Sep 29, 2022, these shares were worth $624.46 million.
We also have iShares Core S&P Smallcap ETF and Vanguard Total Stock Market Index Fund as the top two Mutual Funds with the largest holdings of the Cytokinetics Incorporated (CYTK) shares. Going by data provided on Dec 30, 2022, iShares Core S&P Smallcap ETF holds roughly 7.03 million shares. This is just over 7.42% of the total shares, with a market valuation of $321.9 million. Data from the same date shows that the other fund manager holds a little less at 2.68 million, or 2.83% of the shares, all valued at about 129.71 million.